|
|
The future of effective aerosol therapies
lies in the optimization of drug-to-device and
device-to-drug.
PARI Pharma has taken the
next step and combined
formulation development,
next generation aerosol
platforms, and aerosol characterization under
one roof.
We are currently working on formulations
optimized to our Advanced Aerosol Delivery
platform - eFlow®.
This multifunctional development program is the
key to creating targeted therapies with high
deposition amounts, low side-effect profiles,
improved patient compliance…and happier,
healthier patients.
After 100 years, we know aerosol science
and aerosol delivery.
|
|
|
|
 |
| |
PARI’s eFlow delivers Alnylam RNAi Therapeutic in
Phase II study
[more]
- - - - - - - - - - - - - - - - -
PARI and Kamada Announce Successful
Phase I Results for Aerosolized Alpha-1 Antitrypsin (AAT)
[more]
- - - - - - - - - - - - - - - - -
PARI’s eFlow delivers Alnylam RNAi
Therapeutic in Phase I study
[more]
- - - - - - - - - - - - - - - - -
PARI’s eFlow
included in Gilead’s NDA Submission for Aztreonam Lysine for
Inhalation
[more]
|
|
| |
|
